Free Trial
NASDAQ:HTFL

Heartflow Q2 2025 Earnings Results & Report

Heartflow logo
$49.84 -0.48 (-0.96%)
As of 10:42 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Heartflow missed analyst earnings expectations but beat on revenue in its Q2 2025 results, released September 19, 2025. The company reported EPS of -$1.46 versus the -$0.20 consensus estimate, while revenue of $43.42 million topped the $43.20 million estimate by $0.22 million.

Earnings Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call
8:30 AM ET

Heartflow EPS Results

Actual EPS
-$1.46
Consensus EPS
-$0.20
Beat/Miss
Missed by -$1.26
One Year Ago EPS
N/A

Heartflow Revenue Results

Actual Revenue
$43.42 million
Expected Revenue
$43.20 million
Beat/Miss
Beat by +$220.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Heartflow Q2 2025 Earnings FAQ

Heartflow (NASDAQ:HTFL) reported earnings of -$1.46 per share for Q2 2025, missing the consensus estimate of -$0.20. The report was announced on Friday, September 19, 2025.

Heartflow reported revenue of $43.42 million for Q2 2025, against a consensus estimate of $43.20 million.

Heartflow Earnings Headlines

The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
Heartflow (NASDAQ:HTFL) Raised to "Buy" at Wall Street Zen
BCSM Exits Heartflow (HTFL) on Competitive Concerns
See More Heartflow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Heartflow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Heartflow and other key companies, straight to your email.

About Heartflow

Heartflow (NASDAQ:HTFL) is a medical technology company focused on improving the diagnosis and management of coronary artery disease. The company develops software and clinical tools that use artificial intelligence, advanced image analysis and data from coronary computed tomography angiography (CCTA) scans to provide noninvasive assessments of blood flow and potential blockages in the heart.

Its principal product is the HeartFlow Analysis, which creates a personalized, three-dimensional model of a patient’s coronary arteries and can estimate the impact of blockages on blood flow. The technology is designed to help physicians evaluate chest pain, identify patients who may benefit from additional intervention and support treatment planning without initially relying on invasive catheter-based procedures.

Founded in 2007, HeartFlow serves hospitals, health systems and physicians. Its technology has been used in the United States and select international markets, including countries in Europe and Asia, subject to applicable regulatory clearances and healthcare practices. The company’s operations are centered on developing and commercializing software-based cardiovascular diagnostic solutions.

View Heartflow Profile